Peter’s scientific background lies in the fields of condensed matter physics, biophysics, and bioinformatics. He was a top-2 most cited Russian physicist under 35 and has conducted research at the Kurchatov Institute, one of the leading government science agencies in Russia, AMOLF (a national research center in the Netherlands), and the University of Innsbruck. Peter studied theoretical physics at the Moscow Institute of Physics and Technology and obtained his Ph.D. from the University of Amsterdam. He currently has over 70 publications in peer-reviewed journals and holds multiple patents.
As an MIPT researcher and Head of the Biological Systems Simulation Lab, he works on modeling complex biological systems using methods from statistical physics, kinetics, and physical dynamics. As a biotech entrepreneur, he has led projects in research and pre-clinical development of anti-inflammatory, anti-infectious, and anti-aging compounds, as well as technology licensing and drug discovery collaborations with major pharmaceutical companies (including members of the global top 20) and academic institutions.
Peter is the Founder and CEO of Gero LLC.
Gero is an AI-driven drug discovery company using large-scale human medical data to identify innovative therapeutics. Its flagship project is a pipeline of longevity-focused therapies. Recent results include experimental treatments that reduce biological age and frailty in mice. Gero collaborates with leading academic partners, including Brian Kennedy, Aubrey de Grey, Robert J. Shmookler Reis, Vadim Gladyshev, Yuri Aulchenko, Andrei Gudkov, and others, to translate aging biology into life-changing interventions targeting biological aging acceleration in cancer, metabolic disorders, and immunosenescence.
